Oncology Medical News about test dose

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen
Bone Marrow Transplantation, 06/23/09

Beri R et al. - In patients who had a test dose, a significant correlation between the first and subsequent doses of BU during the conditioning regimen was observed. The findings may allow more centers to pursue transplant strategies with targeted BU by overcoming the time limitation for PK studies during the conditioning regimen.

Exclusive Author Commentary
D Rondelli, 06/23/09

The use of targeted doses of busulfan allows us to give to every patient the right dose of chemotherapy prior to a stem cell transplant. Because busulfan pharmacokinetics studies are not performed in the majority of the hospitals, it may be difficult for many centers to arrange for these tests to be obtained within 24-48 hours. By showing that a test dose 2 weeks before transplant is reliable and does not require the doctors to receive the results within 24-48 hours we hope to facilitate the use of targeted busulfan in many transplant centers.